The current standards of care involve using anti-VEGF agents, which selectively target extracellular VEGF. We've been doing this for years and those drugs do a good job, but there are limitations ...

Please provide your email address to receive an email when new articles are posted on . Intravitreal bevacizumab may contribute to the need for longer ventilation support and a reduced chance of ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease ...

New study from University of California, Irvine and University of California, Santa Barbara researchers demonstrates improved retinal function and vascular integrity, supporting further investigation ...

Please provide your email address to receive an email when new articles are posted on . There are more options available than just the standard methods. Choices need to be made for every step of the ...

Findings showed the difference in mean change in BCVA at week 12 between ONS-5010 and ranibizumab was -1.009 letters. Topline data were announced from a phase 3 trial demonstrating ONS-5010 ...

STOCKHOLM — Simple changes, like minimizing patient visits and reducing the use of nonsterile gloves, can make a big difference in the environmental impact of intravitreal injections without ...

A dexamethasone implant significantly outperformed ranibizumab (Lucentis) and methotrexate for intravitreal treatment of persistent/recurrent uveitic macular edema, according to results of a ...

The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.